Want to see FR:ALERS full AI Analyst Report?
ALERS Stock Chart & Stats
€21.00
-€0.30(-1.43%)
At close: 4:00 PM EDT
€21.00
-€0.30(-1.43%)
Day’s Range― - ―
52-Week Range€19.30 - €25.70
Previous CloseN/A
Volume62.00
Average Volume (3M)968.00
Market Cap
€200.11M
Enterprise Value€240.50
Total Cash (Recent Filing)€20.66M
Total Debt (Recent Filing)€16.02M
Price to Earnings (P/E)42.6
Beta-0.18
Next Earnings
Oct 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.47
Shares Outstanding10,248,871
10 Day Avg. Volume1,061
30 Day Avg. Volume968
Financial Highlights & Ratios
PEG Ratio2.53
Price to Book (P/B)1.36
Price to Sales (P/S)1.48
P/FCF Ratio39.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.13
Revenue Forecast (FY)€175.90M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetA low debt-to-equity (~0.09) provides durable financial flexibility, lowering default and refinancing risk. This buffer supports continued R&D, selective M&A or capex, and cushions operational shocks—helping sustain strategic initiatives over the next 2–6 months.
Recurring Consumables-Driven ModelRevenue tied to repeat reagent and consumable purchases creates predictable, high-frequency demand and customer lock-in. Installed instruments drive follow-on consumable pull-through, underpinning durable annuity-like revenue and supporting steady cash generation over the medium term.
Solid Gross Margins & Stabilizing RevenueGross margins in the 40–46% range provide a structural cushion to absorb pricing or cost volatility while funding operations and incremental product investment. Combined with returning top-line growth in 2024–2025, this supports sustainable revenue base and reinvestment capacity.
Bears Say
Weakened Profitability TrendA structural step-down in profitability versus prior years suggests lasting margin pressure—potentially from pricing, competitive dynamics, or mix shifts. This reduces free earnings available for reinvestment and shareholder return, weakening durable earnings power.
Free Cash Flow DeteriorationA meaningful decline in free cash flow and weaker cash conversion (FCF ≈ one-third of net income) constrains the company’s ability to self-fund capex, R&D, or acquisitions and reduces financial optionality. It raises exposure to working-capital shocks and limits durable capital allocation.
Volatile Returns On EquityLarge swings in ROE and a near-zero ROE in 2025 indicate inconsistent earnings quality and difficulty converting capital into sustained returns. This volatility complicates forecasting, undermines investor confidence, and signals structural issues in profit conversion.
Eurobio-Scientific SA News
ALERS FAQ
What was Eurobio-Scientific SA’s price range in the past 12 months?
Eurobio-Scientific SA lowest stock price was €19.30 and its highest was €25.70 in the past 12 months.
What is Eurobio-Scientific SA’s market cap?
Eurobio-Scientific SA’s market cap is €200.11M.
When is Eurobio-Scientific SA’s upcoming earnings report date?
Eurobio-Scientific SA’s upcoming earnings report date is Oct 13, 2026 which is in 71 days.
How were Eurobio-Scientific SA’s earnings last quarter?
Eurobio-Scientific SA released its earnings results on Apr 10, 2026. The company reported €0.248 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Eurobio-Scientific SA overvalued?
According to Wall Street analysts Eurobio-Scientific SA’s price is currently Overvalued.
Does Eurobio-Scientific SA pay dividends?
Eurobio-Scientific SA does not currently pay dividends.
What is Eurobio-Scientific SA’s EPS estimate?
Eurobio-Scientific SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eurobio-Scientific SA have?
Eurobio-Scientific SA has 10,248,871 shares outstanding.
What happened to Eurobio-Scientific SA’s price movement after its last earnings report?
Eurobio-Scientific SA reported an EPS of €0.248 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Eurobio-Scientific SA?
Currently, no hedge funds are holding shares in FR:ALERS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Eurobio-Scientific SA
Eurobio Scientific S.A. specializes in the conceptualization, development, and distribution of sophisticated diagnostic products. Its key therapeutic and research domains include transplantation, infectious illnesses, life sciences, and oncology. The company's portfolio features the Tetanus Quick Stick, an essential emergency diagnostic for rapidly determining a patient's tetanus vaccination status. It also distributes cell culture media, molecular biology reagents, and proprietary antibody solutions. Proprietary developments from Eurobio Scientific encompass the BJI InoPlex, a multiplex serological test for diagnosing prosthetic joint infections, and the EBX-044 PCR test, utilized for identifying SARS-CoV-2 variants. Its licensed offerings include AlloMap, a gene-expression profiling blood test designed for the ongoing surveillance of heart transplant recipients. The firm, initially named Diaxonhit, changed its corporate identity to Eurobio Scientific S.A. in June 2018. Founded in 1997, the company is headquartered in Les Ulis, France.
Technical Analysis
MAUNA KEA TECHNOLOGIES
―
Novacyt
―
Diagnostic Medical Systems
―
Ikonisys SA
―
Median Technologies
―